Pharvaris (PHVS) Capital Leases (2023 - 2024)
Pharvaris (PHVS) posted Capital Leases of -$19.2 billion for Q3 2024, up 59.0% on a QoQ basis from -$46.9 billion in Q4 2023.
Pharvaris (PHVS) Capital Leases (2023 - 2024) Analysis & Trends
Pharvaris' Capital Leases history runs 2 years deep, the most recent figure standing at -$19.2 billion for Q3 2024.
- Quarterly Capital Leases changed N/A year-over-year to -$19.2 billion in Q3 2024, while the trailing twelve-month figure through Sep 2024 was -$19.2 billion (changed N/A YoY) and the FY2023 annual result came in at -$47.1 billion, changed N/A from the prior year.
- Capital Leases was -$19.2 billion for Q3 2024 at Pharvaris, up from -$46.9 billion in the prior quarter.
- Across five years, Capital Leases topped out at -$19.2 billion in Q3 2024 and bottomed at -$46.9 billion in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Pharvaris | 2.17 Bn | 1.88 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -19.22 Bn |
| Dec 31, 2023 | -46.87 Bn |